Biofrontera’s Ameluz Gel FDA Approval for Higher Dosage

Biofrontera ( (BFRI) ) just unveiled an update.

Biofrontera Inc. announced FDA approval for increasing the maximum dosage of its Ameluz® gel from one to three tubes per treatment, offering enhanced flexibility for dermatologists treating actinic keratosis on the face and scalp. This expanded use is supported by clinical studies confirming the safety and efficacy of the higher dosage. The company is now working towards securing reimbursement for the updated dosage, signaling a significant advancement in photodynamic therapy options for patients.

For a thorough assessment of BFRI stock, go to TipRanks’ Stock Analysis page.